COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention group: Patients take Sakarya-20 pharyngeal inhalation solution along with standard treatments. Sakarya-20 contains: a complex of nanoparticles (gold, silver and iron) with a total concen
Sponsors
Personal
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Admission of Covid-19 patients over 18 years of age who are diagnosed based on a number of clinical coronary symptoms (dry cough, fever, headache, sore throat, lymphopenia or thrombocytopenia) by a physician and confirmed by PCR-viral diagnostic test load test (swallowing of the throat and nose) is performed in the laboratory. COVID-19 patients with mild to moderate disease who do not need to be admitted to the coronary ward (no lung involvement or very little involvement confirmed by CT scan) are included in the study if they are satisfied.
Exclusion criteria
Exclusion criteria: Age under 18, Lung involvement (need to be hospitalized), malignant tumor and other acute systemic diseases, co-infection with HIV, tuberculosis, history of asthma, asthma-like attacks and respiratory problems, life-threatening comorbidity Consumption of any other pharyngeal inhaler, pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virus clearance. Timepoint: Before and after intervention. Method of measurement: Polymerize chain reaction test using thermocycler. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of oxygen saturation. Timepoint: Before and after the intervention. Method of measurement: Oximeter.;Clinical symptoms changes. Timepoint: Before and after the intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Rezazadeh
Azad University, Tehran Medical Sciences Branch
Outcome results
None listed